Overview

Update
Acquisitions
1 Acquisition
Total Equity Funding
$20.04M in 4 Rounds from 2 Investors
Headquarters:
San Carlos, CA
Description:
Eiger is a biopharmaceutical company developing new antiviral agents against novel targets in the treatment of hepatitis.
Founders:
Categories:
Health Care, Biotechnology, Medical
Website:
http://www.eigerbio.com
Social:

Company Details

Update

Eiger BioPharmaceuticals is a privately held biotechnology company developing a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Eiger’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.

Funding Rounds (6) - $26.04M

Update
DateAmount / RoundValuationLead InvestorInvestors
Apr, 2016$3M / Venture0
Mar, 2016undisclosed amount / Debt Financing1
Nov, 2015$6M / Debt Financing0
Nov, 2015undisclosed amount / Venture0
Feb, 2015$8.74M / Series A2
Feb, 2009$8.3M / Series A2

Acquisitions (1)

Update
DateAcquiredAmount
Nov 18, 2015Unknown

Current Team (9)

Update

Board Members and Advisors (3)

Update

Offices/Locations (1)

Update
  • Headquarters

    PO Box 430

    San Carlos, CA 94070

    USA

Past Team (1)

Update

Images (1)

Update

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos